Featured
Search Clinical Trials
Terminated
Clinical Performance Evaluation of the C2i-Test (External Link)
The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome …
Baylor Role:
Collaborator
Terminated
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (External Link)
Avelumab is a fully human monoclonal PD-L1 antibody of the immunoglobulin G1 (IgG1) subclass. It works by binding to PD-L1 on tumor cells, immune cells and/or stromal cells. This prevents …
Baylor Role:
Lead Sponsor
Terminated
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal (External Link)
Everolimus has significantly improved outcomes following prior therapy. This study is a biomarker driven Phase II trial that will assess the activity of everolimus as first-line therapy for renal cell …
Terminated
Genetic Susceptibility to Kidney Cancer (External Link)
This study will further the understanding of the genetic events leading to the development of RCC; explore the genetic basis for genetic instability and how it affects cancer risk; and …
Baylor Role:
Lead Sponsor